Cisplatin exerts an additional series of immunomodulant effects: upregulation of major histocompatibility complex (MHC) class I on tumor and antigen-presenting cells (APCs), recruitment and proliferation of effector T-cells and APCs, PD-L1 upregulation, IFN production, and downregulation of immunosuppressive myeloid-derived suppressor cells (MDSC) and Tregs [56,57,58,59]. This evidence concerns the gene IFNA1 and neoplasm.